The estimated Net Worth of George Avgerinos is at least $1.69 Million dollars as of 11 December 2018. George Avgerinos owns over 97,325 units of Fortress Biotech Inc stock worth over $449,099 and over the last 9 years he sold FBIO stock worth over $858,320. In addition, he makes $386,347 as Senior Vice President - Biologics Operations at Fortress Biotech Inc.
Sign up
George Avgerinos FBIO stock SEC Form 4 insiders trading
George has made over 8 trades of the Fortress Biotech Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 97,325 units of FBIO stock worth $102,191 on 11 December 2018.
The largest trade he's ever made was selling 97,325 units of Fortress Biotech Inc stock on 11 December 2018 worth over $102,191. On average, George trades about 12,677 units every 26 days since 2015. As of 11 December 2018 he still owns at least 255,170 units of Fortress Biotech Inc stock.
You can see the complete history of George Avgerinos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
George Avgerinos biography
Dr. George C. Avgerinos Ph.D. serves as Senior Vice President - Biologics Operations of the Company. Dr. Avgerinos has served as our Senior Vice President, Biologics Operations since June 2013. Dr. Avgerinos joined us from AbbVie, Inc., where he was Vice President, HUMIRA® Manufacturing Sciences and External Partnerships. In his 22-year career at AbbVie, Inc., formerly Abbott Laboratories, formerly BASF Bioresearch Corporation (BASF), Dr. Avgerinos was responsible for many aspects of biologics development and operations. These included the HUMIRA® operations franchise, global biologics process and manufacturing sciences, biologics CMC, manufacturing operations, and third-party manufacturing. During his tenure, Dr. Avgerinos led and participated in the development of numerous clinical candidates which included the launch of HUMIRA®. He supported expansion of the supply chain to over $9.0 billion in annual global sales. Dr. Avgerinos’ efforts on HUMIRA® have been recognized with numerous awards, including the prestigious Abbott’s Chairman’s award in 2011. Dr. Avgerinos received a B.A. in Biophysics from the University of Connecticut and a Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.
What is the salary of George Avgerinos?
As the Senior Vice President - Biologics Operations of Fortress Biotech Inc, the total compensation of George Avgerinos at Fortress Biotech Inc is $386,347. There are 6 executives at Fortress Biotech Inc getting paid more, with Robyn Hunter having the highest compensation of $1,798,070.
How old is George Avgerinos?
George Avgerinos is 67, he's been the Senior Vice President - Biologics Operations of Fortress Biotech Inc since 2013. There are 3 older and 8 younger executives at Fortress Biotech Inc. The oldest executive at Fortress Biotech Inc is Malcolm Hoenlein, 76, who is the Independent Director.
What's George Avgerinos's mailing address?
George's mailing address filed with the SEC is 2 Gansevoort St, New York, NY 10014, USA.
Insiders trading at Fortress Biotech Inc
Over the last 9 years, insiders at Fortress Biotech Inc have traded over $826,952 worth of Fortress Biotech Inc stock and bought 6,309,522 units worth $9,160,045 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss, and George Avgerinos. On average, Fortress Biotech Inc executives and independent directors trade stock every 77 days with the average trade being worth of $271,550. The most recent stock trade was executed by Lindsay A Md Rosenwald on 11 July 2024, trading 5,000 units of FBIO stock currently worth $37,400.
What does Fortress Biotech Inc do?
fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
What does Fortress Biotech Inc's logo look like?
Complete history of George Avgerinos stock trades at Fortress Biotech Inc and Fortress Biotech Inc
Fortress Biotech Inc executives and stock owners
Fortress Biotech Inc executives and other stock owners filed with the SEC include:
-
Robyn Hunter,
Chief Financial Officer, Treasurer, Secretary -
Michael Weiss,
Executive Vice Chairman - Strategic Development, Director -
Lindsay Rosenwald,
Executive Chairman of the Board, President, Chief Executive Officer -
Robyn M. Hunter,
CFO, Treasurer & Corp. Sec. -
Dr. Lindsay Allan Rosenwald,
Exec. Chairman, Pres & CEO -
Michael S. Weiss Esq.,
Vice Chairman & Exec. Vice Chairman of Strategic Devel. -
George Avgerinos,
Senior Vice President - Biologics Operations -
Eric Rowinsky,
Co-Vice Chairman and Director -
J. Jay Lobell,
Independent Director -
Dov Klein,
Independent Director -
Jimmie Harvey,
Independent Director -
Malcolm Hoenlein,
Independent Director -
Kevin Lorenz,
Independent Director -
Jaclyn Jaffe,
IR Contact Officer -
Dr. Thomas F. Schaible,
Project Leader of Inflammatory Bowel Disease -
David Jin,
Chief Financial Officer -
Lucy Lu,
Director